{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nurix Therapeutics, Inc.
Is Nurix Therapeutics, Inc. technically bullish or bearish?
As of August 26, 2025, Nurix Therapeutics, Inc. is in a bearish trend with strong indicators across multiple time frames, significantly underperforming the S&P 500 with year-to-date and one-year returns of -52.39% and -63.74%, respectively.
Who are in the management team of Nurix Therapeutics, Inc.?
As of March 2022, the management team of Nurix Therapeutics, Inc. includes Dr. David Lacey (Independent Non-Executive Chairman), Dr. Arthur Sands (President and CEO), and several Independent Directors: Dr. Leon Chen, Ms. Julia Gregory, Dr. Lori Kunkel, and Dr. Jeffrey Tong. They oversee the company's strategic direction and operations.
What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on developing oral therapies to modulate protein levels for cancer and immune disorders. As of February 2025, it has a market cap of $868.32 million, with net sales of $18 million and a net loss of $56 million.
How big is Nurix Therapeutics, Inc.?
As of Jun 18, Nurix Therapeutics, Inc. has a market capitalization of 868.32 million, with net sales of 56.41 million and a net profit of -208.41 million over the last four quarters. The company reported shareholder's funds of 526.99 million and total assets of 675.43 million as of Nov 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
